Gotowa bibliografia na temat „Antibody-toxin conjugates – theraputic use”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Antibody-toxin conjugates – theraputic use”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Antibody-toxin conjugates – theraputic use"
Senter, Peter D., Marilyn J. Tansey, John M. Lambert i Walter A. Blattler. "NOVEL PHOTOCLEAVABLE PROTEIN CROSSLINKING REAGENTS AND THEIR USE IN THE PREPARATION OF ANTIBODY-TOXIN CONJUGATES". Photochemistry and Photobiology 42, nr 3 (wrzesień 1985): 231–37. http://dx.doi.org/10.1111/j.1751-1097.1985.tb08936.x.
Pełny tekst źródłaKIEREK-JASZCZUK, DANUTA, RONALD R. MARQUARDT i DAVID ABRAMSON. "Use of a Heterologous Solid-Phase Antigen in an Indirect Competitive Antibody-Capture Enzyme-Linked Immunosorbent Assay for T-2 Mycotoxin". Journal of Food Protection 60, nr 3 (1.03.1997): 321–27. http://dx.doi.org/10.4315/0362-028x-60.3.321.
Pełny tekst źródłaLefeber, Dirk J., Barry Benaissa-Trouw, Johannes F. G. Vliegenthart, Johannis P. Kamerling, Wouter T. M. Jansen, Kees Kraaijeveld i Harm Snippe. "Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-Protein Conjugate Vaccines Related to Streptococcus pneumoniae Type 3". Infection and Immunity 71, nr 12 (grudzień 2003): 6915–20. http://dx.doi.org/10.1128/iai.71.12.6915-6920.2003.
Pełny tekst źródłaChen, Zhaochun, Rachel Schneerson, Julie A. Lovchik, Zhongdong Dai, Joanna Kubler-Kielb, Liane Agulto, Stephen H. Leppla i Robert H. Purcell. "Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax". Clinical and Vaccine Immunology 22, nr 8 (3.06.2015): 902–8. http://dx.doi.org/10.1128/cvi.00137-15.
Pełny tekst źródłaNiculescu-Duvaz, I., i C. J. Springer. "Antibody-Directed Enzyme Prodrug Therapy (ADEPT): A Targeting Strategy in Cancer Chemotherapy". Current Medicinal Chemistry 2, nr 3 (październik 1995): 687–706. http://dx.doi.org/10.2174/092986730203220223143057.
Pełny tekst źródłaTedder, T. F., V. S. Goldmacher, J. M. Lambert i S. F. Schlossman. "Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system." Journal of Immunology 137, nr 4 (15.08.1986): 1387–91. http://dx.doi.org/10.4049/jimmunol.137.4.1387.
Pełny tekst źródłaAkter, Sultana, Teemu Kustila, Janne Leivo, Gangatharan Muralitharan, Markus Vehniäinen i Urpo Lamminmäki. "Noncompetitive Chromogenic Lateral-Flow Immunoassay for Simultaneous Detection of Microcystins and Nodularin". Biosensors 9, nr 2 (18.06.2019): 79. http://dx.doi.org/10.3390/bios9020079.
Pełny tekst źródłaLu, Ying-Jie, Sophie Forte, Claudette M. Thompson, Porter W. Anderson i Richard Malley. "Protection against Pneumococcal Colonization and Fatal Pneumonia by a Trivalent Conjugate of a Fusion Protein with the Cell Wall Polysaccharide". Infection and Immunity 77, nr 5 (2.03.2009): 2076–83. http://dx.doi.org/10.1128/iai.01554-08.
Pełny tekst źródłaPestka, James J. "Enhanced Surveillance of Foodborne Mycotoxins by Immunochemical Assay". Journal of AOAC INTERNATIONAL 71, nr 6 (1.11.1988): 1075–81. http://dx.doi.org/10.1093/jaoac/71.6.1075.
Pełny tekst źródłaPui, CH, FG Behm i WM Crist. "Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia". Blood 82, nr 2 (15.07.1993): 343–62. http://dx.doi.org/10.1182/blood.v82.2.343.343.
Pełny tekst źródłaRozprawy doktorskie na temat "Antibody-toxin conjugates – theraputic use"
Ng, Wai-yun Louisa, i 吳慧欣. "Production of variants of mitogillin with reduced IgE bindingactivity". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B31972093.
Pełny tekst źródła"Construction of a Recombinant Immunotoxin". University of Technology, Sydney. Faculty of Science, 1995. http://hdl.handle.net/2100/270.
Pełny tekst źródła"Construction of a recombinant immunotoxin". Thesis, University of Technology, Sydney. Faculty of Science, 1995. http://hdl.handle.net/10453/20069.
Pełny tekst źródłaIn recent years a number of therapeutically useful immunotoxins have been produced using recombinant gene technology. In general, this involves fusion of a toxin gene with sequence encoding a variety of clinically relevant proteins or peptides. Using these techniques a recombinant immunotoxin has been engineered by fusing the genes encoding an antibody fragment with the sequence of a small cytolytic peptide, melittin. The antibody fragment consists of the antigen binding site derived from a murine monoclonal antibody K- 1-21, which binds to human free kappa light chains and recognises a specific epitope (KMA) expressed on the surface of human myeloma and lymphoma cells. The toxic portion of the molecule is melittin, a 26 amino acid, membrane lytic peptide which is a major component of bee venom. Using PCR a single chain Fv (scFv) was constructed by linking VH and VL genes with an oligonucleotide encoding a flexible, hydrophilic peptide. The melittin gene was synthesised as an oligonucleotide and extended by PCR. Nucleotide sequence encoding a linker peptide was added to the 5' end and a primer encoding a FLAG peptide was used to extend the 3' end. This gene construct was then ligated into the recombinant expression vector, pPOW scFv, to create the fusion gene encoding the recombinant immunotoxin. The gene construct was expressed in the periplasm of E.coli (TOPP2) using the secretion signal pelB . Expression of the foreign protein was monitored by western blot using a monoclonal antibody which recognises the FLAG peptide encoded at the carboxy terminal region of the gene construct. Expression of the recombinant immunotoxin was optimised and the resulting protein was purified using anti-FLAG M2 affinity chromatography. Antigen binding activity was assessed by ELISA and flow cytometry using a human myeloma cell line, HMy2, which expresses the KMA antigen.Binding of the immunotoxin to a control human cell line, K562, which does not express KMA on the cell surface was also assessed. The results indicated that the recombinant immunotoxin retained antigen binding specificity and it was cytotoxic towards the target cell line (HMy2).
Książki na temat "Antibody-toxin conjugates – theraputic use"
Ramakrishnan, S. Cytotoxic conjugates. Austin: R.G. Landes Co., 1993.
Znajdź pełny tekst źródła1960-, Tyle Praveen, i Ram Bhanu P. 1951-, red. Targeted therapeutic systems. New York: Dekker, 1990.
Znajdź pełny tekst źródła1947-, Wiley Ronald G., i Lappi Douglas A, red. Molecular neurosurgery with targeted toxins. Totowa, N.J: Humana Press, 2005.
Znajdź pełny tekst źródłaImmunotoxin Methods and Protocols. Humana Press, 2001.
Znajdź pełny tekst źródłaFrankel, A. Clinical Applications of Immunotoxins (Current Topics in Microbiology and Immunology). Springer-Verlag Telos, 1998.
Znajdź pełny tekst źródłaCarl-Wilhelm, Vogel, red. Immunoconjugates: Antibody conjugates in radioimaging and therapy of cancer. New York: Oxford University Press, 1987.
Znajdź pełny tekst źródłaAntibodydrug Conjugates And Immunotoxins From Preclinical Development To Therapeutic Applications. Springer, 2012.
Znajdź pełny tekst źródła1927-, Baldwin R. W., Byers Vera S i Mann Ronald D. 1928-, red. Monoclonal antibodies and immunoconjugates. Carnforth, Lancs, UK: Parthenon Pub. Group, 1990.
Znajdź pełny tekst źródłaW, Baldwin R., Byers Vera S i Mann R. D. 1928-, red. Monoclonal antibodies and immunoconjugates in cancer treatment. Carnforth: Parthenon Publishing, 1990.
Znajdź pełny tekst źródła1935-, Quash Gerard A., Rodwell John D. 1946-, Institut national de la santé et de la recherche médicale (France) i CYTOGEN Corporation, red. Covalently modified antigens and antibodies in diagnosis and therapy. New York: Dekker, 1989.
Znajdź pełny tekst źródła